Amoxicillin/clavulanic acid associated cholestasis in a patient with chronic hepatitis B: a case report.
We described a patient with history of chronic hepatitis B in whom cholestatic hepatitis occurred after amoxicillin/clavulanic acid (Augmentin) therapy, which to our knowledge is the first case reported in Asia. An atypical serology profile of hepatitis B virus (HBV) markers, demonstrated by negative hepatitis B surface antigen (HBsAg) associated with transient positivity of hepatitis B e antigen (HBeAg) and HBV DNA, was noted during the development of cholestasis.
Yang
W G
WG
Department of Medicine, Veterans General Hospital-Taipei, Taiwan, R.O.C.
Chan
C Y
CY
Lu
C L
CL
Tsay
S H
SH
Lee
S D
SD
D000368:Aged; D000658:Amoxicillin / Q000009:adverse effects; D019980:Amoxicillin-Potassium Clavulanate Combination; D002779:Cholestasis / Q000139:chemically induced*; D002969:Clavulanic Acids / Q000009:adverse effects; D004279:DNA, Viral / Q000032:analysis; D004359:Drug Therapy, Combination / Q000009:adverse effects*; D006509:Hepatitis B / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006801:Humans; D008297:Male
D002969:Clavulanic Acids; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin